thought ahead attr-act data
landscap novel therapi ttr space quit dynam alnylam
ioni activ player orphan diseas patient ttr-mediat amyloidosi
progress cardiac neurolog diseas confer high mortal rate detail
result phase attr-act trial tafamidi expect upcom esc
meet could help defin treatment paradigm base prior discuss
kol see takeaway kol call attr landscap
highlight cardiac amyloidosi specialist call expect competit
efficaci profil reduct composit endpoint favor
safety/toler profil support fda submiss ultim garner us
approv overal view tafamidi posit attr market favor
peak potenti drug part emerg later-stag pipelin
receiv increas visibl late said tafamidi alon isnt suffici move dial
growth-wis wed look pipelin augment like deal mean
drive upsid result rais pt reflect
greater pipelin visibl maintain equal weight rate
expect remain vari street expect call reduct
composit endpoint meaning efficaci threshold though cite
reduct view overli optimist note foa consensu modest
vs reuter estim ahead street
sale becom one pfe blockbust year
near-term competit limit expect competit pressur silenc alnylam
patisiran ioni inotersen cover smid cap analyst gena wang mitig
near-term upon success commerci tafamidi given posit data tafamidi
like broadest label hereditari wt patient repres
major attr patient sizeabl market opportun addit opinion
oral administr tafamidi key differenti factor iv patisiran sc inotersen
rais usd
return equiti ttm
link barclay live interact chart
host call discuss attr-act data monday et investor
access call dial ou pw esc
quarterli annual ep usd
consensu number thomson reuter receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
larg captur upsid key product
prevnar ibranc xtandi absent meaning
busi development/ acquisit see littl
upsid current revenu earn trend
better expect uptak prevnar ibranc
xtandi offset price pressur essenti
coupl pipelin success oncolog
success deploy capit toward could
result upsid forecast
faster eros essenti due price
pressur along lower growth innov could
result weaker top line growth failur deploy
capit pipelin asset could cloud
long-term outlook result share stay
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
manag encourag tafamidi outlook
recent opportun discuss expect monday present well
overal attr market dynam us ou manag
commun efficaci threshold might result us approval/label
expans cardiomyopathi eu believ manag remain posit ahead
monday readout readili prepar file across geographi like ye us
eu accord primari endpoint quit strong either
endpoint composit endpoint two would like garner approv
tafamidi alon like enough move dial overal admit
attr market repres sizeabl opportun potenti tafamidi ultim
becom blockbust manag believ tafamidi potenti blockbust
product cardiomyopathi indic alon thu like room ww revenu
reach beyond given broad
inclus polyneuropathi
eu /cardiomyopathi hereditary/wt patient popul note vyndaqel
tafamidi brand name eu current approv polyneuropathi
manag activ pursu label expans includ cardiomyopathi file
expect base attr-act data well us approv file ye includ
cardiomyopathi potenti polyneuropathi line speak
manag believ us would repres roughli futur tafamidi sale
eu come remain share larg japan
posit ahead data like support fda approv
composit like indic posit efficaci safeti unlik issu
yet commun efficaci threshold would garner fda approv
prior discuss kol suggest like posit trend composit endpoint
death hospit efficaci threshold potenti suffici support
fda approv promot strong physician adopt composit reduct
would extrem impress though note kol emphas comfort
treat patient result yield composit reduct believ
highli achiev given prior top-lin detail regard safeti expect tafamidi
well-toler given gener posit safeti profil eu
trial co-primari endpoint may hit statist signific given small
sampl size endpoint strong clinic accord manag either
endpoint signific composit endpoint enough move forward
would make strong case approv note current
work toward file us well geographi assum see
posit data monday anticip fairli rapid regulatori submiss
sizeabl competit pressur silenc unlik
upon success commerci believ tafamidi unlik compet directli
either alnylam patisiran ioni inotersen compani cover smid cap analyst
gena wang given posit result patient popul wt hereditari
expect pfe label broad ultim includ hereditari wt wild-typ
non-inherit cardiomyopathi patient well current approv polyneuropathi
eu would offer signific market opportun label meet expect
pfizer stabil broadest label presum prefer therapi
wt patient experi predominantli cardiac issu well hereditari patient
suffer cardiomyopathi genet variant class class
patient patient predominantli neuropathi tend
hereditari form diseas like begin treatment silenc could ultim
switch tafamidi minim improv observ month therapi
expect see subgroup analysi attr-act data broken patient
popul hereditari vs wt monday would discuss potenti label
assum would match treatment popul predominantli wt studi
oral formul repres key differenti silenc oral administr
tafamidi signific differenti current inject silenc iv patisiran
subcutan inotersen previous speak kol emphas oral
formul overwhelmingli prefer method administr amongst current
patient given major kol patient treat tertiari center iv
administr repres signific burden patient due long travel time
ad challeng travel neuropathi
next-gen treatment face higher develop barrier look ahead
develop next-gener cardiac attr treatment new treatment
confront high develop barrier order ultim surpass tafamidi
follow repres sever barrier statist signific improv
efficaci key outcomes-bas endpoint surviv hospit rate like
necessit compar trial significantli improv dose administr
infrequ inject consider improv safety/toler
beyond monotherapi approach believ commun may eventu move toward
combin approach given potenti synergi comb differ moa
combin stabil like tafamidi silenc ultim earli
specul kol well manag note exist scientif rational
support potenti develop combin treatment regimen
geoff meacham ph herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli
relat specif recommend view express research report
